New England Journal of Medicine OCTOBER 25, 2021

MONALEESA-2: Ribociclib plus Letrozole in Advanced Breast Cancer

Gabriel N. Hortobagyi et al.

Bottom Line

The phase III MONALEESA-2 trial demonstrated that the addition of the CDK4/6 inhibitor ribociclib to first-line letrozole significantly improves overall survival in postmenopausal women with HR+/HER2- advanced breast cancer.

Key Findings

1. The combination of ribociclib and letrozole significantly improved overall survival compared to letrozole monotherapy, achieving a median overall survival of 63.9 months versus 51.4 months (hazard ratio = 0.76; 95% CI: 0.63-0.93; P = 0.004).

2. This regimen provided a clinically meaningful 24% relative reduction in the risk of death, with the survival benefit emerging approximately 20 months after treatment initiation.

3. The trial also established a robust improvement in progression-free survival (the primary endpoint), with a median of 25.3 months in the ribociclib arm versus 16.0 months in the placebo arm (hazard ratio = 0.568; P = 9.63 × 10^-8).

4. Adverse events were manageable, with neutropenia being the most common grade 3/4 laboratory abnormality; however, these were generally transient and reversible with dose adjustments.

Study Design

Design

RCT

Double-Blind

Sample

668

Patients

Duration

80 mo

Median

Setting

Multicenter, International

Population Postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) recurrent or metastatic breast cancer who had not received prior systemic therapy for advanced disease.

Intervention Ribociclib (600 mg/day; 3-weeks-on/1-week-off) plus letrozole (2.5 mg/day; continuous).

Comparator Placebo plus letrozole (2.5 mg/day; continuous).

Outcome Progression-free survival as assessed by the investigator.

Study Limitations

• The trial population was limited to postmenopausal women, which may restrict the direct generalizability of these findings to younger or premenopausal populations without specific consideration of additional agents like ovarian function suppressors.

• The study required patients to have a performance status that allowed for standard therapy, potentially excluding the most frail patients in the real-world setting.

• Long-term toxicity profiles, while consistent, necessitate ongoing vigilance for specific adverse events such as QTc prolongation and potential hepatic effects.

Clinical Significance

The MONALEESA-2 results established ribociclib plus an aromatase inhibitor as a preferred, standard-of-care first-line treatment regimen for postmenopausal women with HR+/HER2- advanced or metastatic breast cancer, supported by evidence of the longest median overall survival reported in a phase III trial for this patient population at the time.

Historical Context

The MONALEESA-2 trial was instrumental in validating the clinical efficacy of CDK4/6 inhibitors, a therapeutic class that transformed the management of hormone receptor-positive metastatic breast cancer by addressing the near-universal issue of endocrine therapy resistance.

Guided Discussion

High-yield insights from every perspective

Med Student

Medical Student

What is the specific molecular mechanism of ribociclib, and why is it combined with an aromatase inhibitor like letrozole in the treatment of HR+ breast cancer?

Key Response

Ribociclib is a selective inhibitor of Cyclin-Dependent Kinases 4 and 6 (CDK4/6), which mediate the transition from the G1 to the S phase of the cell cycle. In HR+ breast cancer, the cyclin D-CDK4/6-Rb pathway is often overactive. Letrozole reduces the estrogenic drive that promotes cyclin D expression; combining the two provides a dual blockade of the cell cycle, leading to enhanced growth arrest or senescence compared to either agent alone.

Resident

Which specific laboratory and diagnostic monitoring parameters are unique to ribociclib compared to other CDK4/6 inhibitors like palbociclib when managing a patient on the MONALEESA-2 protocol?

Key Response

While all CDK4/6 inhibitors require monitoring for neutropenia, ribociclib specifically requires baseline and periodic EKG monitoring (at day 1 and 14 of the first cycle) due to the risk of QTc prolongation. It also necessitates more frequent liver function test (LFT) monitoring in the first two cycles to detect potential drug-induced hepatotoxicity, a requirement more emphasized for ribociclib than palbociclib.

Fellow

The MONALEESA-2 trial demonstrated a significant Overall Survival (OS) benefit, whereas the PALOMA-2 trial (palbociclib) did not reach statistical significance for OS. Critically analyze the potential reasons for this discrepancy in evidence.

Key Response

Discrepancies may arise from differences in trial design, such as the handling of missing data and the rate of loss to follow-up, which was higher in PALOMA-2. Additionally, biological differences in CDK4 vs. CDK6 potency or the use of subsequent therapies (such as PI3K inhibitors or other CDK4/6 inhibitors) post-progression may influence the OS signal independently of the initial Progression-Free Survival (PFS) benefit.

Attending

With a median OS now exceeding 63 months in the ribociclib arm of MONALEESA-2, how does this long-term data shift the conversation regarding 'endocrine-only' first-line therapy for patients with low-volume disease?

Key Response

The substantial OS benefit (a 12-month absolute improvement) suggests that even in patients with indolent disease, the 'best foot forward' approach is superior. Delaying CDK4/6 inhibition to the second line may result in a loss of survival potential that cannot be fully recovered, effectively moving the threshold for endocrine monotherapy to only those patients with significant contraindications or extremely poor performance status.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD

Assess the impact of 'crossover' and subsequent CDK4/6 inhibitor use on the statistical power of the OS analysis in MONALEESA-2. How might a Marginal Structural Model or Rank Preserving Structural Failure Time (RPSFT) model have altered the interpretation?

Key Response

In trials where the control arm receives the experimental agent upon progression (crossover), the OS benefit is usually diluted. While MONALEESA-2 did not have formal crossover, many control patients received subsequent CDK4/6i. Using causal inference models like RPSFT could potentially reveal an even larger treatment effect by estimating the OS benefit as if the control group had never received the inhibitor, highlighting the drug's true efficacy.

Journal Editor

Despite the impressive OS hazard ratio, what threats to internal validity should a reviewer flag regarding the long-term follow-up and the handling of patients who were unblinded or transitioned to open-label ribociclib?

Key Response

A rigorous reviewer would scrutinize the 'informative censoring' that occurs when patients drop out due to toxicity versus progression. They would also evaluate if the duration of follow-up was sufficient to capture late-onset toxicities and whether the protocol-specified alpha-spending function for interim OS analyses was strictly followed to prevent Type I error inflation during the multi-year reporting process.

Guideline Committee

Based on the OS data from MONALEESA-2, should the recommendation for ribociclib + AI be prioritized over palbociclib + AI in first-line HR+/HER2- MBC guidelines?

Key Response

Current guidelines (NCCN, ASCO) generally group the three CDK4/6 inhibitors as Category 1. However, since ribociclib (MONALEESA-2) and abemaciclib (MONARCH-3) have demonstrated OS benefits in the first-line setting while palbociclib (PALOMA-2) has not, committees are increasingly discussing a 'hierarchy of evidence.' While all are effective for PFS, the level of evidence for OS is now strongest for ribociclib, potentially influencing a 'preferred' status in future iterations.

Clinical Landscape

Noteworthy Related Trials

2012

BOLERO-2 Trial

n = 724 · NEJM

Tested

Everolimus plus Exemestane

Population

Postmenopausal women with HR+ advanced breast cancer resistant to nonsteroidal aromatase inhibitors

Comparator

Placebo plus Exemestane

Endpoint

Progression-free survival

Key result: The addition of everolimus to exemestane significantly improved progression-free survival in women with hormone-receptor-positive advanced breast cancer.

2016

PALOMA-2 Trial

n = 666 · NEJM

Tested

Palbociclib plus Letrozole

Population

Postmenopausal women with ER+/HER2- advanced breast cancer

Comparator

Placebo plus Letrozole

Endpoint

Progression-free survival

Key result: Palbociclib combined with letrozole significantly improved progression-free survival compared with letrozole alone in patients with advanced breast cancer.

2017

MONARCH 3 Trial

n = 493 · JCO

Tested

Abemaciclib plus a nonsteroidal aromatase inhibitor

Population

Postmenopausal women with HR+/HER2- advanced breast cancer

Comparator

Placebo plus a nonsteroidal aromatase inhibitor

Endpoint

Progression-free survival

Key result: The addition of abemaciclib to an aromatase inhibitor resulted in a significantly longer progression-free survival than endocrine therapy alone.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis